Deuruxolitinib: a new entry in the dm+d dictionary
The NHS Business Services Authority (NHS BSA) has added deuruxolitinib to the dm+d (dictionary of medicines and devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of immunomodulatory agents used in dermatology and rheumatology.
What is deuruxolitinib used for?
Deuruxolitinib is indicated for the treatment of atopic dermatitis. It works by selectively inhibiting JAK1, reducing inflammatory signalling in the skin.
Event-medicine relevance
Deuruxolitinib is not currently approved for use in the UK and is not available on the NHS. Medical Responders should not administer this agent at events. However, it is important to be aware of its entry in the dm+d for reference purposes and for awareness of emerging treatments.
If a patient at an event reports taking deuruxolitinib (for example, as part of a clinical trial or obtained privately), they should be advised to seek specialist dermatology review. In the event of acute exacerbation of atopic dermatitis, standard supportive care and conveyance to hospital should be considered as appropriate.
Key points for responders
- Deuruxolitinib is a JAK1 inhibitor used in dermatology
- Not licensed for use in the UK as of the latest BNF update
- Not appropriate for event-medicine administration
- Always verify current licensing status against the BNF and MHRA before considering any clinical use
Further information
For the latest clinical guidance, consult the BNF and MHRA. For dm+d updates and full moiety records, visit the NHS BSA dm+d portal.